It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. Under a mutual ...

Lars Fruergaard Jorgensen's departure comes a week after the company downgraded its sales and profits forecast, and follows a more than 50% decline in the company's shares since mid-2024.

You can reach Andrew on Signal at drewqjoseph.45. LONDON — Lars Fruergaard Jørgensen, who led Novo Nordisk as it rode the boom of its obesity and diabetes medications to become one of the ...

Lars Fruergaard Jorgensen, who has headed the Danish pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.

Danish drugmaker Novo Nordisk announced Friday that CEO Lars Fruergaard Jørgensen will step down, marking a significant leadership shakeup as the company navigates increasing pressure in the ...

Novo Nordisk has announced that Lars Fruergaard Jørgensen will step down as CEO, following a mutual agreement with the company’s board of directors. According to the company, Jørgensen is expected to ...

Hør hvilket udtryk AaB-træneren forventer fra sit AaB-mandskab i videoen her. Lars Kramer søger videre fra AaB efter indeværende sæson. Det meddeler AaB på sin hjemmeside. Her forklarer ...

Lars Fruergaard Jørgensen stopper som administrerende direktør for Novo Nordisk efter gensidig aftale Efter otte år på posten stopper Lars Fruergaard Jørgensen som administrerende direktør ...

The company behind popular new drug Ozempic says its CEO, Lars Fruergaard Jorgensen, will step down following a plunge in the company's share price. Danish pharmaceutical giant Novo Nordisk's ...

Lars Fruergaard Jorgensen’s departure comes a week after the company downgraded its sales and profits forecast and follows a more than 50% decline in the company’s shares since mid-2024.

Lars Fruergaard Jørgensen stopper som administrerende direktør for Novo Nordisk efter gensidig aftale. Efter otte år på posten stopper Lars Fruergaard Jørgensen som administrerende direktør for Novo ...